Why the study?
Inflammation is recognized as a universal pathogenetic link across atherogenesis, plaque rupture, myocardial infarction, repair, and heart failure, motivating an evaluation of anti-inflammatory therapies in ACS.
This review highlights inflammation as a universal pathogenetic link in acute coronary syndrome and discusses the prospects of anti-inflammatory therapies.
Anti-inflammatory therapies in ACS should not yet change practice; leaves open prospects for overcoming implementation barriers in targeted trials.
Theory of atherogenesis and its complications underwent numerous changes. Today we observe that inflammation is a universal pathogenetic link between various processes such as atherosclerosis, rupture of atherosclerotic plaques and following myocardial infarction, post-infarction cardiac repair and heart failure. This review discusses examples, difficulties, and prospects of implementation of anti-inflammatory therapies in management of acute coronary syndrome and its complications.
No takes yet. Share an insight, caveat, or question.
Ryabov et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: